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INTRODUCTION
Asia has the opportunity to be a global leader in combat-
ing the growing epidemic of chronic kidney disease (CKD).
This opportunity should be based on our knowledge of the
strengths (and weaknesses) of the Asian medical and scien-
tific communities and the environments in which they work.
DEMOGRAPHIC ISSUES IN ASIA
Nearly 50% of the global population of nearly 7 billion
persons live in the Asian Pacific region (1). Six of the 10 most
populous nations in the world are in Asia, including the 2
largest (China 1.3+ billion, India 1.1+ billion) along with
Indonesia, Pakistan, Bangladesh and Japan. Population den-
sities range from some of the world’s highest (Macau, Singa-
pore, Hong Kong, Maldives, and Bangladesh-all over 1,000
persons per km2) to some of the lowest (Mongolia and Aus-
tralia-both less than 3 persons per km2).
Asia has both strengths and weaknesses relating to this large
population. In terms of annual gross domestic product (GDP)
3 of the world’s 4 wealthiest nations are in Asia (US$GDP
Japan 4.3×109, China 3.3×109, India 1.1×109), and the
GDP per capita is over US$30×103 in Singapore, Hong
Kong, Brunei, Australia, Japan, and Taiwan; ranking them
in the 22 highest incomes per person in the world (2). How-
ever we also have some of the poorest of people, with GDP
per capita being less than US$2,000 p.a. in Afghanistan, Bur-
ma, Nepal, Bangladesh, Cambodia, The Solomons, and Papua.
The Solomons and Papua New Guinea, and total economies
of GDP less than US$500 million in East Timor, the Solomon
and Tonga (2). 
Though the large population of Asia brings its own chal-
lenges, the world’s pharmaceutical industry has recognised
its strength, with increasing numbers of prospective thera-
peutic trials being carried out in Asia. Regrettably however,
a recent survey found that of 13,152 commercially sponsored
trial sites in the world, Asia had only 2 trial sites per million
population, compared with North America 191 and Europe
86 (3). This strongly suggests that Asian populations are not
being adequately recruited into clinical trials, and hence prop-
erly represented in efficacy and side-effect databases. We must
move to accelerate the trend towards using Asian populations
in sponsored clinical trials. 
Scientifically this population has contributed remarkably
to publications in the last few decades (Fig. 1). In addition
to this, a growing number of publications from institutions
in western countries have authors born in Asia or descended
from Asian parentage. This scientific basis is already enhanc-
ing the two-way communication between Asian and the rest
of the world and is likely to result in Asian leadership over
the next decades.
The cultural diversity within the Asian Pacific region is
arguably greater than any other area in the world. Underpin-
ning the fascinating variety of religions and languages are
important and unique behaviours and values which, though
fundamentally similar, differ in many ways. But in terms of
CKD, the influences of everyday behaviour can have enor-
mous impacts on options for patients and their carers, influ-
encing fundamental decisions such as live and deceased donor
transplantation, self-care or dependent-care, healthcare fund-
ing processes, as well as solutions to clinical problems. The
solutions on CKD problems, varying according to these val-
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Asian Pacific countries include those with the highest incidence of renal failure in the
world, the richest and poorest economies and unparalleled diversity of economy,
culture and geography. From this come many challenges, but also a strong basis
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leader in nephrology in the near future.
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� REVIEW�ues, should provide a basis for combating CKD world-wide.
SPECIAL ASIAN ISSUES
A particularly intriguing issue in the Asian Pacific region
is the striking variance in incidence and prevalence of end-
stage kidney disease (ESKD) as recognised by rates of dialy-
sis and transplantation. In countries with the economic power
to offer dialysis to virtually all citizens, Japan (4) and Taiwan
(5) have the world’s highest incidence and prevalence of ESKD
with those of Korea rapidly accelerating (6), while Australia
has amongst the lowest. This enormous disparity has been
partially related to the impact of diabetes and ageing in Asia
(7) but also seems to involve other factors (8-13).
One study of CKD in our region concluded that the rea-
son for the high rates seen in more wealthy Asian areas was
a combination of increasing incidence of type 2 diabetes and
ageing with an underlying propensity for CKD to progress
more quickly in non-European Asian populations (7). The
widespread social and dietary deprivation of the first half of
the last century, combined with the rapid improvements over
the last 50 yr may be responsible for this, according to the
theory relating malnutrition to low birth weight, fewer pan-
creatic islets and fewer nephrons; hence later life type 2 dia-
betes and progression of CKD (8). It is not quite that sim-
ple. No doubt important ethnic (genetic) influences play a
role, as well as environmental factors such as nutrition, infec-
tion and exposure to toxins (8-13).
Internationally, but stemming mainly from Western coun-
tries, have come classifications and recommended treatment
regimens for a wide variety of CKD issues. Inherent in these
is the assumption of a relatively restricted variety of popula-
tion. Perhaps this is most evident when we look at formulae
for calculating a glomerular filtration rate (GFR) from plas-
ma creatinine. The first widely applied formula, resulting
in an estimate of creatinine clearance (CrCl), was the Cock-
roft-Gault formula which was developed in a Caucasian
Canadian group of 249 patients, using gender, weight and
plasma creatinine (14). The next major step forward was the
formula from the Modification of Diet in Renal Disease
(MDRD) Study, which recognised some ethnicity effects with
a correction to be applied if the patient is black (15). Criti-
cally, since there was no data on Asian persons in the MDRD
study, there was no correction available for the Asians. The
lack of specific GFR formulae for Asian populations is not
an insignificant issue, since it reflects not only on the diag-
nosis and management of those with established CKD, but
also on any attempts to determine the incidence of CKD in
our communities. Fortunately this is rapidly being addressed.
GFR formulae applicable in Japan (16) and China (17) have
been published, and other countries are rapidly following this
lead, either testing the validity of previous formula in their
community as in Korea (18), or attempting new constructs.
A substantive South-Asian formula is eagerly anticipated.
SPECIAL ASIAN DISEASES
While it is clear that Asia is unfortunately following and
perhaps overtaking the Western world in the increase in meta-
bolic syndrome and its related renal consequences, we must
not lose sight of other diseases which are more common in
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Industrial poisons
Lead
Cadmium
Melamine
Insecticides
Plant toxins
Aristolochic acid 
Djenkel beans (djenkolism)
Animal toxins
Snake bite
Wasp sting
Bee sting
Tropical infections
Malaria
Leptospirosis
Typhus
Dengue
Hantavirus
Regional diseases
Hypokalaemic periodic paralysis (Thailand)
Renal tubular acidosis (Thailand, PNG)
Tubulointerstitial nephritis (Sri Lanka)
Increased disease of metabolic origin
Metabolic syndrome (all Asia)
Renal stones (heat, dehydration)
Diabetes (Nauru, Australia Aborigine)
Table 1. Diseases of specific Asian Pacific interest
Fig. 1. Exponential increase in renal publications from Asia since
1985. Graph compiled from Pub Med listed articles published (i)
between 1985 and 2007 (ii) from authors of institutions in Japan,
China, Korea, Taiwan and India (iii) with renal, kidney or nephrol-
ogy in title, abstract or keywords.
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0Asia than in the West (Table 1). This allows concentration
on diseases that are locally preventable, and the knowledge
gained may have global relevance. In developing countries,
poor water supplies, isolated communities and a hot climate
contribute to a high incidence of kidney stones (19) and acute
renal failure due to gastroenteritis, kidney stones and peri
partum bleeding (20, 21). Because of the preponderance of
rural dwellers and heavily forested areas, a wide variety of
reptile and insect bites cause acute renal failure (22-24). Trop-
ical infections are commonly complicated by renal disease
(25-30), including haemorrhagic fever with renal syndrome,
where Korea has played a major role in defining the clinical
aspects and relationship to the Hantaviruses (28-30). The
rapid transition to industrial societies has had adverse envi-
ronmental effects, resulting in industrial poisoning, and in
rural communities improper use of insecticides contributes
to both acute and chronic renal failure (31-34). The inges-
tion of various fungi and fruit has been associated with renal
injury, both acute and chronic (35-37).
In addition, there are areas of Asia where pockets of unusu-
al disease occur; their causes are likely to be environmental
or genetic but they are as yet unknown. In Thailand, renal
tubular acidosis, hypokalaemic periodic paralysis and renal
stone disease occur (38). North Central Sri Lanka has an area
where chronic tubulointerstitial nephritis is common, simi-
lar to aristolochic acid nephropathy, but without evidence of
fungal ingestion. Renal tubular acidosis has been reported
in areas of Papua New Guinea, possibly related to ovalocy-
tosis (39, 40). Consequent upon these regional diseases, Asian
Pacific nephrology has a major opportunity to contribute to
understanding their pathophysiology and management.
Less fortunately, however, most of Asia seems prone not
only to increased renal complications from the metabolic
syndrome, but also it has been suggested that there are more
common or severe examples of other diseases, particularly SLE
(41-43) and IgA nephropathy (44, 45) than in most Euro-
pean communities. The challenge of CKD to Asia will cer-
tainly involve these more traditionally Western issues.
THE FUTURE
Asian nephrology is in an exciting phase. Many have recog-
nised its potential, and the benefits of a committed and col-
laborative approach. The Asian Pacific Society of Nephrolo-
gy (APSN) of which the Korean Society of Nephrology is a
Sponsor Society is now 25 yr old and every Asian national
nephrology society in our region is affiliated. Its journal, Ne-
phrology, is MEDLINE listed and in its 13th year. The next
Congress of the APSN is to be held in Korea in 2010. In
2007 the Asian Forum on Chronic Kidney Disease Initia-
tive (AFCKDI) held the first of what have become annual
meetings to discuss the issues of collaborating CKD in our
region. The 4th AFCDI will likely be held in Korea with
the APCN. Global bodies have quickly become involved
with both the APCN and AFCKDI meetings, with ISN
COMGAN and the Kidney Disease Improving Global Out-
comes (KDIGO) represented at all meetings.
Asian can lead nephrology in the 21st century. It is now
up to all of us to contribute to this collaborative effect.
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